Different faces of hepatocellular carcinoma as a health threat in 21st century

Hepatitis Monthly

Volumn 13, Issue 2, 2013, Pages

  Yeganeh, B ^a   Hashemi, Mohammad ^b,c   De Serres, Fredrick J ^d   Los, Marek J ^e   Ghavami, Saeid ^a,f  

^a UNIVERSITY OF MANITOBA   (Canada)

^b ZAHEDAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ZAHEDAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^e LINKÖPING UNIVERSITY   (Sweden)

^f Manitoba Institute of Child Health   (Canada)

Author keywords

Aflatoxins; Alpha 1 Antitrypsin; Biological markers; Hepatitis B virus; Hepatitis C; Lobaplatin

Indexed keywords

AFLATOXIN; ALPHA FETOPROTEIN; CALGRANULIN A; CALGRANULIN B; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; LOBAPLATIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P27; PROTEIN P53; UNCLASSIFIED DRUG;

ALPHA 1 ANTITRYPSIN DEFICIENCY; ANTIVIRAL THERAPY; BILE DUCT CARCINOMA; CELL DEATH; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; COLORECTAL CARCINOMA; EDITORIAL; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CELL CARCINOMA; LVER TRANSPLANTATION; MIXED INFECTION; NONHUMAN; PROTEIN EXPRESSION; PUBLICATION; RADIOFREQUENCY ABLATION; RISK;

EID: 84875742192     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.9308     Document Type: Editorial

References (46)

1. Hashemi M, Ghavami S. Hepatocellular recurrence after orthotopic liver transplantation: Is combination of alpha-fetoprotein and glypican-3 a reliable marker?: Hepatocellular recurrence after orthotopic liver trasplantation. Hepat Mon.2011;11(3):155-6.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin.2011;61(2):69-90.
3. Sherman M. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver Dis.2010;30(1):3-16.
4. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol.2008;48 Suppl 1:S20-37.
5. Abu El Makarem M. An overview of biomarkers for the diagnosis of hepatocellular carcinoma. Hepat Mon.2012;12(10 HCC):e6122.
6. Harstrick A, Bokemeyer C, Scharnofkse M, Hapke G, Reile D, Schmoll HJ. Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and -resistant human testicular, ovarian, and gastric carcinoma cell lines. Cancer Chemother Pharmacol. 1993;33(1):43-7.
7. McKeage MJ. Lobaplatin: a new antitumour platinum drug. Expert Opin Investig Drugs.2001;10(1):119-28.
8. Sternberg CN, de Mulder P, Fossa S, Kaye S, Roberts T, Pawinsky A, et al. Lobaplatin in advanced urothelial tract tumors. The Genitourinary Group of the European Organization for Research and Treatment of Cancer (EORTC). Ann Oncol.1997;8(7):695-6.
9. Dai HY, Liu L, Qin SK, He XM, Li SY. Lobaplatin suppresses proliferation and induces apoptosis in the human colorectal carcinoma cell Line LOVO in vitro. Biomed Pharmacother.2011;65(3):137-41.
10. Gietema JA, Guchelaar HJ, de Vries EG, Aulenbacher P, Sleijfer DT, Mulder NH. A phase I study of lobaplatin (D-19466) administered by 72 h continuous infusion. Anticancer Drugs.1993;4(1):51-5.
11. Wang Z, Tang X, Zhang Y, Qi R, Li Z, Zhang K, et al. Lobaplatin induces apoptosis and arrests cell cycle progression in human cholangiocarcinoma cell line RBE. Biomed Pharmacother. 2012;66(3):161-6.
12. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin.2005;55(2):74-108.
13. Yamashita T, Honda M, Kaneko S. Molecular mechanisms of hepatocarcinogenesis in chronic hepatitis C virus infection. J Gastroenterol Hepatol.2011;26(6):960-4.
14. Rodriguez-Mendez ML, Gonzalez-Quintela A, Aguilera A, Barrio E. Prevalence, patterns, and course of past hepatitis B virus infection in intravenous drug users with HIV-1 infection. Am J Gastroenterol. 2000;95(5):1316-22.
15. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol.2006;44(1 Suppl):S6-9.
16. Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS.2005;19(6):593-601.
17. Lacombe K, Rockstroh J. HIV and viral hepatitis coinfections: advances and challenges. Gut.2012;61 Suppl 1:i47-58.
18. Zidan A, Scheuerlein H, Schule S, Settmacher U, Rauchfuss F. Epidemiological pattern of hepatitis B and hepatitis C as etiological agents for hepatocellular carcinoma in iran and worldwide. Hepat Mon.2012;12(10 HCC):e6894.
19. Ng J, Wu J. Hepatitis B-and hepatitis C-related hepatocellular carcinomas in the United States: similarities and differences. Hepat Mon.2012;12(10 HCC):e7635.
20. Kew MC. Hepatitis B virus / human immunodeficiency virus coinfection and its hepatocarcinogenic potential in sub-saharan black africans. Hepat Mon.2012;12(10 HCC):e7876.
21. Cauchy F, Fuks D, Belghiti J. HCC: current surgical treatment concepts. Langenbecks Arch Surg.2012;397(5):681-95.
22. Du Y, Su T, Ding Y, Cao G. Effects of antiviral therapy on the recurrence of hepatocellular carcinoma after curative resection or liver transplantation. Hepat Mon.2012;12(10 HCC):e6031.
23. Hashemi M, Alavian SM, Ghavami S, de Serres FJ, Salehi M, Doroudi T, et al. High prevalence of alpha 1 antitrypsin phenotypes in viral hepatitis B infected patients in Iran. Hepatol Res.2005;33(4):292-7.
24. Hashemi M, Naderi M, Rashidi H, Ghavami S. Impaired activity of serum alpha-1-antitrypsin in diabetes mellitus. Diabetes Res Clin Pract.2007;75(2):246-8.
25. Lee P, Gildea TR, Stoller JK. Emphysema in nonsmokers: alpha 1-antitrypsin deficiency and other causes. Cleve Clin J Med.2002;69(12):928-9.
26. de Serres FJ, Blanco I, Fernandez-Bustillo E. Genetic epidemiology of alpha-1 antitrypsin deficiency in North America and Australia/ New Zealand: Australia, Canada, New Zealand and the United States of America. Clin Genet.2003;64(5):382-97.
27. de Serres FJ, Blanco I, Fernandez-Bustillo E. Genetic epidemiology of alpha-1 antitrypsin deficiency in southern Europe: France, Italy, Portugal and Spain. Clin Genet.2003;63(6):490-509.
28. Topic A, Ljujic M, Radojkovic D. Alpha-1-antitrypsin in pathogenesis of hepatocellular carcinoma. Hepat Mon.2012;12(10 HCC):e7635.
29. Blanco I, de Serres FJ, Carcaba V, Lara B, Fernandez-Bustillo E. Alpha-1 Antitrypsin Deficiency PI*Z and PI*S Gene Frequency Distribution Using on Maps of the World by an Inverse Distance Weighting (IDW) Multivariate Interpolation Method. Hepat Mon.2012;12(10 HCC):e7434.
30. Ghavami S, Chitayat S, Hashemi M, Eshraghi M, Chazin WJ, Halayko AJ, et al. S100A8/A9: a Janus-faced molecule in cancer therapy and tumorgenesis. Eur J Pharmacol.2009;625(1-3):73-83.
31. Halayko AJ, Ghavami S. S100A8/A9: a mediator of severe asthma pathogenesis and morbidity? Can J Physiol Pharmacol. 2009;87(10):743-55.
32. Ghavami S, Eshragi M, Ande SR, Chazin WJ, Klonisch T, Halayko AJ, et al. S100A8/A9 induces autophagy and apoptosis via ROSmediated cross-talk between mitochondria and lysosomes that involves BNIP3. Cell Res.2010;20(3):314-31.
33. Ghavami S, Kerkhoff C, Chazin WJ, Kadkhoda K, Xiao W, Zuse A, et al. S100A8/9 induces cell death via a novel, RAGE-independent pathway that involves selective release of Smac/DIABLO and Omi/HtrA2. Biochim Biophys Acta.2008;1783(2):297-311.
34. Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S, Srikrishna G. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol. 2008;181(7):4666-75.
35. Maletzki C, Bodammer P, Breitruck A, Kerkhoff C. S100 proteins as diagnostic and prognostic markers in colorectal and hepatocellular carcinoma. Hepat Mon.2012;12(10 HCC):e7240.
36. Kim HR, Kim TW. Occupational hepatic disorders in Korea. J Korean Med Sci.2010;25(Suppl):S36-40.
37. Hussain SP, Schwank J, Staib F, Wang XW, Harris CC. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene.2007;26(15):2166-76.
38. Uccello M, Malaguarnera G, Corriere T, Biondi A, Basile F, Malaguarnera M. Risk of hepatocellular carcinoma in workers exposed to chemicals. Hepat Mon.2012;12(10 HCC):e5943.
39. Wogan GN, Newberne PM. Dose-response characteristics of aflatoxin B1 carcinogenesis in the rat. Cancer Res.1967;27(12):2370-6.
40. Wu HC, Santella R. The role of aflatoxins in hepatocellular carcinoma. Hepat Mon.2012;12(10 HCC):e7238.
41. Tazuma S. Gallstone disease: Epidemiology, pathogenesis, and classification of biliary stones (common bile duct and intrahepatic). Best Pract Res Clin Gastroenterol.2006;20(6):1075-83.
42. Yeh MM. Pathology of combined hepatocellular-cholangiocarcinoma. J Gastroenterol Hepatol.2010;25(9):1485-92.
43. Al Hamoudi W, Khalaf H, Allam N, Al Sebayel M. Coincidental occurrence of hepatocellular carcinoma and cholangiocarcinoma (collision tumors) after liver transplantation: a case report. Hepat Mon.2012;12(10 HCC):e5871.
44. Fabregat I, Roncero C, Fernandez M. Survival and apoptosis: a dysregulated balance in liver cancer. Liver Int.2007;27(2):155-62.
45. Bassullu N, Turkmen I, Dayangac M, Yagiz Korkmaz P, Yasar R, Akyildiz M, et al. The Predictive and Prognostic Significance of c-erb-B2, EGFR, PTEN, mTOR, PI3K, p27, and ERCC1 Expression in Hepatocellular Carcinoma. Hepat Mon.2012;12(10 HCC):e7492.
46. Izumi N. Recent advances of radiofrequency ablation for early hepatocellular carcinoma. J Gastroenterol Hepatol.2011;26 Suppl 1:115-22.